SUDARSHAN quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
Sudarshan Pharma Industries Ltd reported sales of ₹216.97 Cr, operating profit of ₹20.59 Cr (OPM 9.49%) and net profit of ₹7.78 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.
SUDARSHAN quarterly results (₹ Cr)
Metric
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
115.66
161.59
145.26
168.87
168.01
220.92
174.42
216.97
Expenses
107.69
145.66
134.22
159.66
157.14
200.72
158.52
196.38
Operating Profit
7.97
15.93
11.04
9.21
10.87
20.2
15.9
20.59
OPM
6.89%
9.86%
7.6%
5.45%
6.47%
9.14%
9.12%
9.49%
Other Income
0.51
-0.81
1.21
1.86
1.52
4.13
1.22
1.93
Interest
4
4.4
5.96
5.94
6.28
7.53
8.21
10.36
Depreciation
0.63
0.83
0.88
0.9
0.91
1.09
1.41
1.36
Profit before tax
3.85
9.89
5.41
4.23
5.2
15.71
7.5
10.8
Tax
24.94%
25.08%
26.8%
8.51%
20.19%
27.43%
25.33%
27.96%
Net Profit
2.88
7.41
3.96
3.87
4.15
11.4
5.61
7.78
EPS in Rs
0.12
0.31
0.17
0.17
0.18
0.45
0.23
0.32
SUDARSHAN profit & loss, annual (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
357
461
464
505
703
780
Expenses
346
446
441
465
652
713
Operating Profit
11
15
23
40
51
68
OPM
3.1%
3.2%
4.9%
8%
7%
9%
Other Income
0
1
3
0
9
9
Interest
3
5
9
16
26
32
Depreciation
1
1
1
2
4
5
Profit before tax
7
9
15
22
31
39
Tax
26%
26%
25%
26%
23%
-
Net Profit
5
7
11
16
23
29
EPS in Rs
0.36
0.29
0.48
0.66
0.97
1.18
Dividend Payout
0%
10%
0%
0%
0%
-
SUDARSHAN balance sheet (₹ Cr)
Metric
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Equity Capital
24
24
24
24
25
Reserves
88
107
116
131
170
Borrowings
105
171
219
285
392
Other Liabilities
67
100
148
202
175
Total Liabilities
283
402
507
642
762
Fixed Assets
26
48
53
104
99
CWIP
2
23
28
3
8
Investments
14
30
2
0
0
Other Assets
242
302
424
534
655
Total Assets
283
402
507
642
762
SUDARSHAN cash flows (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
-4
-29
6
-32
-2
Cash from Investing Activity
-1
-26
-5
-21
-78
Cash from Financing Activity
4
66
-12
53
79
Net Cash Flow
-1
11
-12
0
-1
Free Cash Flow
-5
-43
2
-54
-51
CFO/OP
-19%
-179%
36%
96%
7%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit